Vitale Mark A, Vanbeek Corinne, Spivack John H, Cheng Bin, Geller Jeffrey A
Center for Hip and Knee Replacement, Department of Orthopaedic Surgery, New York Presbyterian Medical Center, Columbia University, New York, NY, USA.
Geriatr Orthop Surg Rehabil. 2011 Jul;2(4):128-34. doi: 10.1177/2151458511417434.
Patients with acute hip fractures who are on maintenance warfarin for anticoagulation present a significant challenge and their management remains controversial. The purpose of this study was to assess thromboembolic and systemic complications associated with pharmacological reversal of warfarin-associated coagulopathy in a population of geriatric patients with hip fractures.
This retrospective cohort study identified patients with operative hip fractures on oral warfarin therapy who had an international normalized ratio (INR) >1.50 on admission (N = 93) approximately over a 13-year span. The control group consisted of patients whose warfarin was held upon admission without further intervention preoperatively (n = 23). The treatment group consisted of patients who underwent pharmacologic reversal of elevated INR with vitamin K and/or fresh frozen plasma (FFP) in addition to holding warfarin (n = 70). Primary outcomes included thromboembolic and other complications as well as mortality within 3 months of presentation. Time to surgery was a secondary outcome.
The 3-month mortality rate was 4% in the pharmacological intervention group and 17% in the watch-and-wait group; this difference trended toward statistical significance (P = .06). There were no significant differences in the likelihoods of other thromboembolic or nonthromboembolic complications between groups. While the difference in mean time to surgery was not significantly different overall between groups, this difference was significant in a subgroup of patients with higher baseline INRs (n = 46, INR >2.17), with a mean difference of 4.0 fewer days until surgery in the pharmacological intervention group (P < .01).
Pharmacological reversal of warfarin-associated coagulopathy with a combination of vitamin K and FFP appears to be a safe way to optimize patients for operative fixation of hip fractures and is associated with a shorter delay to surgery in patients with more elevated INRs preoperatively.
retrospective cohort study (level III).
正在接受华法林抗凝治疗的急性髋部骨折患者面临重大挑战,其治疗方案仍存在争议。本研究旨在评估老年髋部骨折患者中,华法林相关凝血病药物逆转治疗所带来的血栓栓塞及全身并发症。
这项回顾性队列研究纳入了口服华法林治疗的髋部骨折手术患者,这些患者在入院时国际标准化比值(INR)>1.50,研究跨度约为13年,共93例。对照组由入院时停用华法林且术前未进行进一步干预的患者组成(n = 23)。治疗组由除停用华法林外,还接受维生素K和/或新鲜冰冻血浆(FFP)进行INR升高的药物逆转治疗的患者组成(n = 70)。主要结局包括血栓栓塞及其他并发症以及就诊后3个月内的死亡率。手术时间为次要结局。
药物干预组3个月死亡率为4%,观察等待组为17%;这一差异有统计学意义的趋势(P = 0.06)。两组间其他血栓栓塞或非血栓栓塞并发症的发生率无显著差异。虽然两组总体平均手术时间差异无统计学意义,但在基线INR较高的亚组患者中(n = 46,INR >2.17)差异显著,药物干预组平均手术延迟时间少4.0天(P < 0.01)。
维生素K和FFP联合使用对华法林相关凝血病进行药物逆转,似乎是使髋部骨折手术固定患者达到最佳状态的安全方法,且与术前INR较高患者的手术延迟时间缩短有关。
回顾性队列研究(III级)。